News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Jun 10, 2021

Summary Toggle aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody

Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2. aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways which are implicated in immune-mediated diseases. SAN DIEGO , June 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.
May 25, 2021

Summary Toggle aTyr Pharma Strengthens Board of Directors with Appointment of Dr. Sara Zaknoen

SAN DIEGO , May 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Sara Zaknoen , M.D., to the company’s Board of Directors.
May 19, 2021

Summary Toggle aTyr Pharma Presents Preclinical Research Highlighting Mechanistic Insights into Tumor Inhibitory Effects of ATYR2810

Findings advance understanding of mechanistic impact of blocking NRP2/VEGF signaling axis with ATYR2810 on aggressive tumor cells SAN DIEGO , May 19, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines
May 13, 2021

Summary Toggle aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update

Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter. Preclinical data for IND candidate ATYR2810 showed anti-tumor effects in models of TNBC and NSCLC. Bispecific antibody project with subsidiary Pangu BioPharma achieved milestones for first of
May 12, 2021

Summary Toggle aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestones for First Year of Government Grant to Develop Bispecific Antibody Platform

Two-year grant awarded by the Hong Kong Government’s Innovation and Technology Commission is funding the development of new bispecific antibodies targeting NRP2 SAN DIEGO , May 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and
May 11, 2021

Summary Toggle aTyr Pharma Announces Promotion of Leslie Nangle, Ph.D., to Vice President of Research

SAN DIEGO , May 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the promotion of Leslie Nangle , Ph.D., to Vice President, Research. Dr.
May 6, 2021

Summary Toggle aTyr Pharma to Webcast Conference Call Reporting First Quarter 2021 Financial Results

Management to host conference call and webcast on May 13th at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , May 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today
Apr 20, 2021

Summary Toggle aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Steroids and Sarcoidosis

Panel discussion on steroids and sarcoidosis to be held on Tuesday, April 27 at 12:00pm ET / 9:00am PT SAN DIEGO , April 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel
Apr 14, 2021

Summary Toggle aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810

SAN DIEGO , April 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and Lonza today announced that the companies have entered into an agreement for the
Apr 9, 2021

Summary Toggle aTyr Pharma Presents Preclinical Research Showing Effects of ATYR2810 in Lung and Breast Cancer at the 2021 AACR Virtual Annual Meeting

Findings demonstrate tumor inhibitory effects of ATYR2810 when used as a monotherapy or in combination with chemotherapy in models of non-small cell lung cancer. ATYR2810 used in combination with chemotherapy or bevacizumab increased anti-tumor effects in triple-negative breast cancer model.